Core Viewpoint - The company is actively expanding its business in the insurance and healthcare sectors by leveraging advanced technology and strategic partnerships to enhance its service offerings and operational efficiency [1][2][3][4]. Group 1: Business Strategy - The company is focusing on key regions and deepening relationships with lighthouse clients, particularly in the healthcare insurance sector [1]. - The company is exploring new sustainable business models and project opportunities to drive growth [1]. Group 2: Insurance Business Development - The company is deepening cooperation with leading insurance institutions, particularly in the area of intelligent medical review, which has shown significant results [2]. - In 2025, the company achieved revenue of RMB 9.963 million from medical-related claims review services in the insurance industry, marking a substantial increase of 1386.8% compared to the same period in 2024 [2]. - A new cooperation agreement was signed in 2025 to extend services to additional areas of auto insurance claims risk control, indicating a deepening partnership with a major property insurance company [2]. Group 3: Healthcare Collaboration - The company signed a strategic cooperation framework agreement with the Guangxi Medical Security Bureau to promote the innovative application of artificial intelligence in healthcare [3]. - The collaboration aims to enhance the digitalization of medical security and explore AI applications in the integration of medical, medical insurance, and pharmaceutical sectors [3]. Group 4: Project Opportunity Expansion - The company is integrating its medical data processing capabilities and risk control technology to deepen its presence in the insurance claims risk control market [4]. - There is a growing demand for specialized and intelligent regulatory technology in the healthcare fund supervision sector, which the company aims to address with its cross-domain expertise [4].

（於中華人民共和國註冊成立的股份有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責任。 UNISOUND AI TECHNOLOGY CO., LTD. 雲知聲智能科技股份有限公司 2 （股份代號：9678） 自願性公告 最新業務進展 本公告乃由雲知聲智能科技股份有限公司（「本公司」）自願作出，旨在知會本公司股東 及潛在投資者有關本公司的最新業務發展情況。 在業務領域上，本公司持續貫徹立足重點區域、深挖燈塔客戶的策略，在醫療保險領域 深入挖掘並拓展邊界；在經營策略上，本公司大力嘗試新的可持續商業模式並積極探 索新型項目機會。 在保險業務領域，本公司憑藉成熟的技術能力與豐富的行業經驗，持續深化與頭部保 險機構的合作，並積極拓展業務邊界與服務模式，為業務規模化發展奠定堅實基礎。其 中，與某頭部財產保險公司（「該財險公司」）的合作成果尤為顯著。繼2024年雙方在智能 醫療審核項目上達成深度合作，成功完成系統在全國範圍內的推廣上線後，該系統憑藉 精準的風險 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 雲知聲智能科技股份有限公司 (於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09678 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 41,621,883 | RMB | | 1 RMB | | 41,621,883 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 41,621,883 | RMB | | 1 RMB | | 41,621,883 | | 2. 股份分類 ...

Core Insights - Company reported strong growth momentum in its first financial report since listing, with a revenue of 405 million RMB for the first half of 2025, representing a year-on-year increase of 20.2% [1] - The large model business experienced a remarkable revenue surge of 457% year-on-year, reaching nearly 100 million RMB, becoming the main driver of the company's performance [1][4] - Recent government policies align closely with the company's core business, providing robust support for future development [1][6] Business Growth Drivers - The core driver of the company's growth is the continuous technological upgrades and commercialization of the Shanhai large model [2] - The Shanhai model has undergone significant advancements since its upgrade to the GPT architecture in May 2023, integrating cutting-edge technologies such as retrieval-augmented generation and multi-modal fusion [2] - The model has achieved three major technological breakthroughs, enhancing its capabilities in mixed reasoning, multi-modal input, and context protocol integration [2] Revenue Breakdown - Daily life scenarios are the main revenue source, contributing 335 million RMB, accounting for 82.7% of total revenue [4] - The medical scenario generated 70 million RMB, representing 17.3% of total revenue, with significant growth quality [4] - The medical applications based on the Shanhai model have been successfully implemented in multiple healthcare institutions, improving service efficiency and quality [4] Policy Alignment - The company's business strategy is well-aligned with national policy directions, particularly the recent "Artificial Intelligence+" initiative [6] - The policy aims for deep integration of AI with six key sectors by 2027, emphasizing the importance of smart terminals and healthcare applications [6] - This policy environment creates vast growth opportunities for the company, leveraging its technological advancements and practical experience in the smart terminal and healthcare sectors [6] Future Outlook - The company plans to continue advancing its general large model foundation, expert-level models, and chip optimization technologies [8] - With dual support from technological development and policy backing, the company is expected to strengthen its core competitiveness and sustain positive performance [8]

云之声(09678)跌超8%，截至发稿，跌8.96%，报716港元，成交额2720.29万港元。 值得注意的是，云知声已获恒生指数有限公司选定并将纳入恒生指数系列的成分股，自2025年9月8日起 生效，其中包括恒生综合指数、恒生综合中小型股指数、恒生互联网科技业指数等。 消息面上，云之声近日发布2025年中期业绩，收益4.05亿元(人民币，下同)，同比增长20.2%;期内亏损 2.98亿元，同比增加16.6%;公司拥有人应占亏损2.97亿元，同比扩大16.4%;每股基本亏损4.28元。 ...

智通财经APP获悉，云之声(09678)跌超8%，截至发稿，跌8.96%，报716港元，成交额2720.29万港元。 消息面上，云之声近日发布2025年中期业绩，收益4.05亿元(人民币，下同)，同比增长20.2%;期内亏损 2.98亿元，同比增加16.6%;公司拥有人应占亏损2.97亿元，同比扩大16.4%;每股基本亏损4.28元。 值得注意的是，云知声已获恒生指数有限公司选定并将纳入恒生指数系列的成分股，自2025年9月8日起 生效，其中包括恒生综合指数、恒生综合中小型股指数、恒生互联网科技业指数等。 ...

Core Viewpoint - The Hong Kong IPO market is active, with 57 new listings and a total fundraising amount of 131.9 billion HKD as of August 25. However, many companies face challenges in meeting both domestic and Hong Kong regulatory requirements for listing [1]. Group 1: Hong Kong IPO Overview - As of August 25, 2023, there have been 57 new IPOs on the Hong Kong Stock Exchange, raising a total of 131.9 billion HKD [1]. - There are currently 211 companies that have submitted applications for listing in Hong Kong [1]. Group 2: Listing Challenges - Companies looking to list in Hong Kong must comply with both domestic laws and Hong Kong's regulatory framework, making the IPO preparation process complex and demanding [1]. Group 3: Resources for Companies - A compilation of Hong Kong listing rules and disclosure documents for domestic companies planning to list in Hong Kong has been organized to assist businesses in understanding the latest regulatory dynamics [1].

Core Insights - The company Yunzhisheng, known as the "first AGI stock in Hong Kong," released its first interim performance report since its listing on June 30, 2025, showcasing strong stock performance and rising market valuation expectations, with a market capitalization of HKD 60 billion [3] - The latest interim report indicates a robust market attitude, with revenues of RMB 404.5 million for the first half of 2025, representing a year-on-year growth of 20.2%, driven significantly by its core large model business, which contributed nearly RMB 100 million [4][5] Financial Performance - Revenue for the first half of 2025 reached RMB 404.967 million, up 20.2% from RMB 337.048 million in the same period last year [5] - The cost of sales and services increased by 23.9% to RMB 274.125 million, while gross profit rose by 13.0% to RMB 130.842 million [5] - The company reported a loss of RMB 298.330 million, a 16.6% increase compared to the previous year's loss of RMB 255.758 million [5] Business Model Transformation - The revenue structure is undergoing a significant transformation, with the core business in daily life and healthcare showing stability, contributing approximately 83% of total revenue [9] - The self-developed "Shanhai Large Model" generated RMB 98.76 million, a substantial increase of 457.4% year-on-year, marking a shift from labor-intensive project-based services to technology-intensive platform/model services [11] Strategic Positioning - The company has established a comprehensive technology stack from foundational infrastructure to top-level application solutions, enhancing its competitive edge [12][14] - The strategic focus is on high-value, high-barrier verticals, particularly in healthcare and daily life, demonstrating significant customer stickiness and market demand [17] Alignment with National Strategy - The release of the national "Artificial Intelligence +" strategy aligns with the company's focus, emphasizing the integration of AI with economic and social development [6][22] - The company aims to develop industry-specific large models and intelligent agents, targeting L3-level AGI capabilities, which aligns with national goals for AI advancement [22][24] Future Outlook - The interim report suggests that Yunzhisheng is on the verge of a critical transformation, with the potential for a significant increase in the proportion of revenue from large model-related services, indicating a possible earlier-than-expected profitability turning point [25]

Core Insights - The article highlights the impressive financial performance of Cloud Know Voice, marking its transition to an AGI-focused company with significant revenue growth driven by large models [1][27] - The report indicates that large models are becoming a direct revenue growth engine for AI companies, showcasing a clear business model and technological path [1][27] Financial Performance - In the first half of 2025, Cloud Know Voice reported total revenue of 405 million RMB, a 20.2% increase from 337 million RMB in the same period of 2024 [1][6] - Revenue from large models surged by 457% to nearly 100 million RMB [1][6] - The medical sector saw a revenue increase of 22.3%, contributing 70 million RMB, which accounted for 17.3% of total revenue [5][6] Business Segmentation - Daily life services generated 335 million RMB, making up 82.7% of total revenue, with solutions contributing 283 million RMB (69.8% of total revenue) [4][5] - The insurance claims review service experienced explosive growth, with revenue increasing by 1386.8% to 9.963 million RMB [7][6] R&D and Technological Advancements - The company invested 168 million RMB in R&D, representing 41.5% of total revenue, with 68.7% of employees dedicated to R&D [9][6] - The "Shan Hai Medical Model" upgrade allowed the company to offer higher-end solutions at increased prices, enhancing its competitive edge [7][9] Strategic Alignment - Cloud Know Voice's business strategy aligns with the Chinese government's "Artificial Intelligence+" initiative, focusing on daily life and medical applications [11][15] - The company has developed a comprehensive AGI technology capability, integrating foundational chips, computational facilities, and large models [19][25] Market Position and Future Outlook - The company is positioned to capitalize on the growing demand for AI solutions in critical sectors like healthcare and daily life, indicating a robust market opportunity [28][29] - The successful commercialization of large models and the ability to provide high-value solutions in serious scenarios reflect the company's strong market presence and potential for long-term growth [28][29]

Core Insights - Company reported a significant revenue growth of 20.2% year-on-year, reaching 405 million RMB for the first half of 2025, with large model revenue soaring by 457% to nearly 100 million RMB [1] - The global AI market is expanding due to technological breakthroughs and policy support, driving strong demand [1] - The company achieved rapid growth in its daily life and medical business segments, with daily life revenue accounting for 82.7% and medical revenue for 17.3% of total revenue [1] Revenue Breakdown - Daily life business generated 335 million RMB, with solution sales revenue increasing by 22.6% to 283 million RMB [1] - AI chip shipments reached 16.5 million units, totaling nearly 100 million units shipped as of June 30, 2025 [1] - In the medical sector, the average customer price rose by 116.2% to 1.013 million RMB, while insurance business revenue surged by 1386.8% [1] R&D Investment - The company invested 168 million RMB in R&D, representing 41.5% of total revenue, to maintain its leading position in the AI industry [2] - Achievements include ranking first in multiple MedBench evaluations and contributing to the drafting of three national standards for AI large models [2] - Future plans involve leveraging the Atlas infrastructure to advance various AI technologies and build sustainable competitive advantages [2]